A Comprehensive Overview on BHF PROTECT TAVI & Cerebral Embolic Protection

Published: 12 June 2023

  • Views:

    Views Icon 13279
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 1
    Full Interview
    Tessel Vossenberg, Rajesh Kharbanda
    Up Next
Average (ratings)
No ratings
Your rating

Overview

In this exclusive interview, Dr Tessel Vossenberg (Medical Center Leeuwarden, Leeuwarden, NL) speaks with Prof Rajesh Kharbanda (Oxford University Hospitals NHS Foundation Trust, UK), Principal Investigator of the BHF PROTECT TAVI trial. This highly anticipated trial aims to provide groundbreaking insights into the field of Cerebral Embolic Protection (CEP) in TAVI.

 

In this interview, Dr Tessel Vossenberg (Medical Center Leeuwarden, Leeuwarden, NL) and Prof Rajesh Kharbanda (Oxford University Hospitals NHS Foundation Trust, UK) delve into the unique aspects of the BHF PROTECT TAVI trial, highlighting its distinguishing features compared to previous studies. They provide a comprehensive overview of the trial's current progress, shedding light on its outcomes, learnings, and potential clinical implications.

 

Moreover, the interview focuses on why the BHF PROTECT TAVI trial holds immense value for future considerations of CEP in TAVI. Prof Rajesh Kharbanda (Oxford University Hospitals NHS Foundation Trust, UK) and Dr Tessel Vossenberg (Medical Center Leeuwarden, Leeuwarden, NL) discuss the potential impact of this trial on daily clinical practice, particularly in assessing stroke risk during TAVI procedures.

 

Furthermore, the interview addresses the significance of CEP in TAVI patients, emphasising the potentially life-altering consequences of stroke and its associated costs. By exploring the current status of CEP and its impact on patients, this interview provides a comprehensive update on the subject.

 

 

 

 

The interview is supported by Boston Scientific

Learning Objectives

  • Identify and analyse the main outcomes, learnings, and clinical implications of the PROTECTED TAVR trial
  • Understand the design of the BHF PROTECT TAVI trial, including its differences from previous studies and assess its current status and progress
  • Recognise the potential significance of BHF PROTECT TAVI in assessing daily clinical practice considerations for stroke risk in TAVI
  • Assess the current status of Cerebral Embolic Protection in TAVI, its impact on patients undergoing TAVI procedures, and the associated cost implications

Target Audience

  • Clinical Cardiologists
  • Interventional Cardiologists
  • Cardiac Surgeons
  • Neurologists

More from this programme

Part 1

Watch the full interview A Comprehensive Overview on BHF PROTECT TAVI & Cerebral Embolic Protection

Faculty Biographies

Tessel Vossenberg

Tessel Vossenberg

Dr Tessel Vossenberg studied Medicine at the University of Amsterdam. Dr Tessel Vossenberg is particularly interested in complex coronary interventions, and structural heart diseases interventions such as mitral valve, tricuspid valve and aortic valve (TAVI) interventions. In addition, she has specialised in coronary physiology and microvascular coronary artery disease.

View full profile
Rajesh Kharbanda

Rajesh Kharbanda

Professor

Prof Rajesh Kharbanda, Consultant Cardiologist in Oxford, graduated from Edinburgh Medical School in 1991, and has trained and worked in the speciality of cardiology in London, Cambridge, Toronto (Canada).

View full profile

Comments

You must be to comment. If you are not registered, you can register here.